What long-term side effects can happen with Keytruda?
Keytruda (pembrolizumab) is an immune checkpoint inhibitor. Because it works by changing immune activity, some side effects can be long-lasting, recur after treatment stops, or appear months after starting. Common long-term concerns people ask about include ongoing inflammation in organs such as the lungs, colon (diarrhea/colitis), liver (hepatitis), endocrine glands (thyroid, adrenal, pituitary), and skin, as well as nervous system effects. The main point for patients is that many immune-related side effects are manageable when they’re recognized early and treated appropriately. [1][2]
How are long-term Keytruda side effects managed in practice?
Management typically follows a “treat early and adjust therapy” approach used for immune-related adverse events:
- Clinicians monitor closely for symptoms that signal organ inflammation (new cough or shortness of breath, persistent diarrhea, abdominal pain, yellowing of skin/eyes, severe fatigue, new headaches, vision changes, or new muscle weakness). [1][2]
- Treatment may include corticosteroids or other immune-suppressing medications depending on which organ is affected and how severe it is. [1][2]
- If side effects are significant, Keytruda may be paused or discontinued and then restarted only if it’s safe. [1][2]
- Some endocrine side effects (like hypothyroidism) can become chronic and require ongoing hormone replacement rather than stopping the drug permanently. [1]
This means “manageable” often looks like either controlling inflammation with medication and follow-up, or taking longer-term hormone replacement when glands are affected. [1][2]
Can side effects improve over time, or do they last permanently?
Some immune-related side effects resolve after treatment and steroids are tapered, while others can persist. Endocrine problems are one area where longer-term treatment is common, because once immune-mediated gland damage happens, hormone replacement may be lifelong. [1]
For other organ toxicities (like lung or colon inflammation), symptoms can often improve with treatment, but long-term follow-up is still important because flare-ups can occur. [1][2]
Are there risks that are harder to manage long term?
Some patients worry about rare but serious complications. Keytruda carries warnings for immune-related complications that can be life-threatening, including severe inflammation in organs (for example, pneumonitis or colitis) and other severe immune reactions. These are manageable for many people, but they require urgent medical attention and prompt treatment. [1][2]
What symptoms mean you should seek care urgently?
Patients are typically advised to report symptoms that could reflect immune toxicity. In the Keytruda prescribing information, guidance emphasizes contacting a clinician promptly for serious or persistent symptoms and following the drug-specific safety plan. [1][2]
Practically, clinicians treat urgent symptoms such as:
- Severe or worsening shortness of breath, chest pain, or persistent cough (possible lung inflammation)
- Severe diarrhea, blood in stool, or severe abdominal pain (possible colon inflammation)
- Yellow skin/eyes, dark urine, or severe right-sided abdominal pain (possible liver inflammation)
- Severe headaches, vision changes, confusion, or new weakness (possible neurologic/endocrine issues)
- Fainting, severe dizziness, or profound fatigue (possible endocrine issues)
Does “manageable” depend on how severe the side effect is?
Yes. Management and outcomes depend heavily on severity (mild vs. moderate vs. severe) and which organ is affected. The prescribing information describes dose modifications and interruption/discontinuation strategies based on severity, along with immune-suppression when needed. [1][2]
That same framework is why early reporting matters: mild symptoms can sometimes be controlled with less intensive steps than severe ones. [1][2]
Who should be involved in long-term monitoring?
Long-term management often involves the oncology team plus specialists based on the organ involved (endocrinology for thyroid/adrenal/pituitary issues, gastroenterology for colitis, pulmonology for pneumonitis, etc.). The need for coordinated follow-up is part of why many side effects are considered “manageable” rather than “unavoidable.” [1][2]
What should patients ask their doctor before continuing Keytruda long term?
Useful questions include:
- What side effects should I watch for based on my treatment and symptoms so far?
- If a side effect happens, what is the step-by-step plan to control it?
- How will you monitor labs for endocrine, liver, and other issues?
- If I have an endocrine problem, will I need lifelong hormone replacement?
- At what severity do you pause or stop therapy?
These questions align with the monitoring and dose-modification approach described in the prescribing information. [1][2]
Are there alternatives if side effects become hard to manage?
If immune-related toxicity becomes severe or recurrent, clinicians may stop Keytruda and choose another treatment strategy appropriate for the cancer type and patient situation. The prescribing information supports treatment interruptions/discontinuation for severe toxicity. [1][2]
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125514s175lbl.pdf
[2] https://www.keytruda.com/safety-and-side-effects